Legal & General Group
ATNM icon

Legal & General Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Legal & General Group’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,713
Closed -$5.96K – 3427
2025
Q1 		$5.96K Hold
3,713
– – ﹤0.01% 3252
2024
Q4 		$4.68K Hold
3,713
– – ﹤0.01% 3339
2024
Q3 		$6.98K Buy
3,713
+580
+19% +$2.29K ﹤0.01% 3335
2024
Q2 		$23.2K Buy
3,133
+115
+4% +$947 ﹤0.01% 2962
2024
Q1 		$23.6K Hold
3,018
– – ﹤0.01% 2905
2023
Q4 		$15.3K Buy
3,018
+433
+17% +$2.23K ﹤0.01% 3135
2023
Q3 		$15.3K Sell
2,585
-558
-18% -$3.71K ﹤0.01% 3132
2023
Q2 		$23.3K Buy
+3,143
New +$26.7K ﹤0.01% 3050

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Legal & General Group's ATNM Position: Q2 2025 in Review

Legal & General Group sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 3,713 shares — an estimated $5.96K sold.

Legal & General Group first reported a position in ATNM in Q2 2023 and held it in 8 quarters. The position peaked at $23.6K in Q1 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Legal & General Group reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 3,713 Actinium Pharmaceuticals shares in Q2 2025, an estimated $5.96K.
  • Legal & General Group first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Legal & General Group's Actinium Pharmaceuticals position peaked at $23.6K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.